-
Compass Therapeutics NasdaqCM:CMPX Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
Location: 80 Guest Street, Boston, MA, 02135, United States | Website: https://www.compasstherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
184.1M
Cash
112.6M
Avg Qtr Burn
-11.04M
Short % of Float
8.58%
Insider Ownership
19.79%
Institutional Own.
70.00%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tovecimig (CTX-009) (DLL4 and VEGF-A bispecific antibody) Details Biliary Tract Cancer | Phase 2/3 Data readout | |
CTX-009 (DLL4 and VEGF-A bispecific antibody) Details Cancer, Colorectal cancer | Phase 2 Initiation | |
CTX-471 +/- KEYTRUDA® (pembrolizumab) Details Cancer, Small cell lung cancer, Non-small cell lung carcinoma, Melanoma | Phase 2 Initiation | |
CTX-8371 (PD-1 x PD-L1) Details Cancer, Solid tumor/s | Phase 1 Data readout | |
CTX-10726 (PD-1 x VEGF-A bispecific antibody) Details Solid tumor/s | IND Submission |